Abstract

RECENT ADVANCE OF NANOTECHNOLOGY FOR THE TREATMENT OF OCULAR DISEASE

Meenakshi K. Chauhan and Geetanjali Khanna*

Abstract

Nanoformulation are use as an alternative for traditional ophthalmic formulation. Their are various factors that creats problem in treatment of ocular disease like rapid elimination, enzymatic drug degradation, Protein binding and physiological barrier etc. All these factors cause reduction in intraocular residence time and poor bioavailability. Recent research study shows that nanoformulation can enhance the therapeutic efficacy and bioavailability of ocular drugs compared to conventional ocular formulation. The various research study in number of patent shows significant increase in therapeutic efficacy for various chronic disease states of both anterior and posterior ocular segments. The nanoformulation approach enhance the ocular bioavailability by reducing the drug protein binding, increasing the corneal resident time, enhancing the drug permeability and also providing a sustained drug release. United States Food and Drug Administration (USFDA) has approved ocular drugs employing nanotechnology and future developments.

Keywords: Ocular drug delivery system, Patent, Nanotechnology, United States Food and Drug Administration.